2009 HBV Symposium

This symposium was titled “Drug-resistant and Vaccine-escape Hepatitis B Virus Mutants: Emergence and Surveillance”. It was held June 4 and 5, 2009 at the CDC’s Roybal Campus in Atlanta. A unique array of international experts presented the latest findings and there was ample opportunity for an exchange of ideas and a discussion of strategies for surveillance of emerging mutants.

Thursday, June 4, 2009

12 noon	Light refreshments
Introduction
1:00 p.m.	Welcome John Ward, CDC
1:15 p.m.	CDC’s viral hepatitis surveillance Scott Holmberg, CDC
Session I : Contexts of HBV mutant emergence and clinical implications (Moderators: John Ward, CDC, & Susan Stramer, American Red Cross, Gaithersburg, MD)
1:30 p.m.	Molecular genesis of drug-resistant and vaccine-escape HBV mutants Stephen Locarnini, Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia
2.00 p.m.	Q & A
2:10 p.m.	HBV S-gene mutants in chronic hepatitis B patients given nucleos(t)ide-analog therapy Chau-Ting Yeh, Chang Gung University, Taipeh, Taiwan
2:40 p.m.	Q & A
2.50 p.m.	Multidrug-resistant HBV mutants Anna Lok, University of Michigan, Ann Arbor, MI
3.20 p.m.	Q & A
3.30 p.m.	Virology and clinical sequelae of HBV mutants in HIV/HBV-coinfected patients given HAART Chloe Thio, Johns Hopkins University, Baltimore, MD
4:00 p.m.	Q & A
4:10 p.m.	Break
Session II : Settings for surveillance for HBV mutants (Moderators: David Bell, CDC, & Anna Lok, University of Michigan, Ann Arbor, MI)
4:30 p.m.	Breakthrough HBV infection in vaccinated Taiwanese children Mei-Hwei Chang, National Taiwan University, Taipei, Taiwan
5:00 p.m.	Q & A
5:10 p.m.	Breakthrough HBV infection in vaccinated American blood donors Susan Stramer, American Red Cross, Gaithersburg, MD
5:40 p.m.	Q & A
5:50 p.m.	HBV/HIV-coinfected patients receiving HAART: the French HIV-HBV Cohort Study Karine Lacombe, INSERM UMR-S707, Paris, France
6.20 p.m.	Q & A
6.30 p.m.	HBV/HIV-coinfected South African patients receiving first-line ART Adrian Di Bisceglie, St Louis University, St Louis, MN
7.00 p.m.	Q & A
7.10 p.m.	Evening Reception
9.00 p.m.	Adjourn

Friday, June 5, 2009

7:30 a.m.	Breakfast
Session III: Laboratory approaches to surveillance (1) (Moderators: Chong-Gee Teo, CDC, & David Durantel, INSERM U871, Lyon, France)
8:30 a.m.	CDC’s surveillance for drug-resistant HIV Walid Heneine, CDC
9.00 a.m.	Q & A
9.10 a.m.	Deep sequencing and network analysis of HBV genomes Yuri Khudyakov, CDC
9.40 a.m.	Q & A
9.50 a.m.	Databases for characterizing HBV mutants and their hosts Carla Kuiken, Los Alamos National Laboratory, Los Alamos, NM
10.20 a.m.	Q & A
10.30 a.m.	Drug-resistant HBV variants: genotypic determinants and phenotypic alterations Daniel Tenney, Bristol-Myers Squibb, Wallingford, CT
11.00 a.m.	Q & A
11.10 a.m.	Break
Session IV: Laboratory approaches to surveillance (2) (Moderators: Kris Krawczynski, CDC, & Stephen Locarnini, Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia)
11.30 a.m.	Fitness and infectivity of drug-resistant and -cross-resistant HBV mutants David Durantel, INSERM U871, Lyon, France
12.00 noon	Q & A
12.10 p.m.	Modulation of HBV secretion by mutations in the S gene Shuping Tong, Brown University, Providence, RI
12.40 p.m.	Q & A
12.50 p.m.	Lunch
1.30 p.m.	Serological profiling of HBsAg mutants Paul Coleman, Abbott Diagnostics, Abbott Park, IL
2.00 p.m.	Q & A
2.10 p.m.	Infectivity of S-gene HBV mutants in vaccinated chimpanzees Saleem Kamili, CDC
2.40 p.m.	Q & A
Session V: Roundtable (Moderator: John Ward, CDC)
2.50 p.m.	Future directions in anti-HBV therapeutics Tim Block, Drexel University & Hepatitis B Foundation, Doylestown, PA
3.05 p.m.	Implications for clinical management Adrian Di Bisceglie, St Louis University, St Louis, MN
3.20 p.m.	Forging laboratory tools for surveillance Chong-Gee Teo, CDC
3.35 p.m.	Implications for vaccination Trudy Murphy, CDC
3.50 p.m.	Discussion
4:15 p.m.	Adjourn